149 related articles for article (PubMed ID: 38842106)
1. Multicenter expanded access program for access to investigational products for amyotrophic lateral sclerosis.
Neel DV; Baselga-Garriga C; Benson M; Keegan M; Chase M; D'Agostino D; Drake K; Hagar JL; Hasenoehrl MG; Kulesa-Kelley J; Leite A; Mohapatra S; Portaro SM; Pothier LM; Rosenthal J; Sherman AV; Yu H; McCaffrey A; Ho D; Luppino S; Bedlack R; Heitzman D; Ajroud-Driss S; Katz J; Felice K; Whitaker C; Ladha S; Alameda G; Locatelli E; Qureshi IA; Hotchkin MT; Hayden MR; Cudkowicz ME; Babu S; Berry JD; Paganoni S
Muscle Nerve; 2024 Aug; 70(2):232-239. PubMed ID: 38842106
[TBL] [Abstract][Full Text] [Related]
2. Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS).
Yerton M; Winter A; Gelevski D; Addy G; Kostov A; Lieberman C; Weber H; Doyle M; Kane G; Cohen C; Parikh N; Burke KM; Rohrer M; Stirrat T; Bruno M; Hochman A; Luppino S; Scalia J; D'Agostino D; Sinani E; Yu H; Drake K; Hagar J; Sherman AV; Babu S; Berry JD; Cudkowicz ME; Paganoni S
Muscle Nerve; 2023 Jun; 67(6):456-463. PubMed ID: 36929648
[TBL] [Abstract][Full Text] [Related]
3. CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS).
Bireley JD; Morren JA
Expert Opin Investig Drugs; 2023; 32(8):677-683. PubMed ID: 37642362
[TBL] [Abstract][Full Text] [Related]
4. Study protocol of RESCUE-ALS: A Phase 2,
Vucic S; Kiernan MC; Menon P; Huynh W; Rynders A; Ho KS; Glanzman R; Hotchkin MT
BMJ Open; 2021 Jan; 11(1):e041479. PubMed ID: 33431491
[TBL] [Abstract][Full Text] [Related]
5. Safety and activity of anti-CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol.
Gelevski D; Addy G; Rohrer M; Cohen C; Roderick A; Winter A; Carey J; Scalia J; Yerton M; Weber H; Doyle M; Parikh N; Kane G; Ellrodt A; Burke K; D'Agostino D; Sinani E; Yu H; Sherman A; Agosti J; Redlich G; Charmley P; Crowe D; Appleby M; Ziegelaar B; Hanus K; Li Z; Babu S; Nicholson K; Luppino S; Berry J; Baecher-Allan C; Paganoni S; Cudkowicz M
Muscle Nerve; 2023 May; 67(5):354-362. PubMed ID: 36533976
[TBL] [Abstract][Full Text] [Related]
6. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
Puthumana J; Miller JE; Kim J; Ross JS
JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
[TBL] [Abstract][Full Text] [Related]
7. The current state of understanding of oncology expanded access programs in Malaysia.
Yong FL; Tan WC
Med J Malaysia; 2024 Mar; 79(2):191-195. PubMed ID: 38553925
[TBL] [Abstract][Full Text] [Related]
8. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.
Vucic S; Menon P; Huynh W; Mahoney C; Ho KS; Hartford A; Rynders A; Evan J; Evan J; Ligozio S; Glanzman R; Hotchkin MT; Kiernan MC
EClinicalMedicine; 2023 Jun; 60():102036. PubMed ID: 37396808
[TBL] [Abstract][Full Text] [Related]
11. New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022.
Jiang J; Wang Y; Deng M
Front Pharmacol; 2022; 13():1054006. PubMed ID: 36518658
[TBL] [Abstract][Full Text] [Related]
12. Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients.
Jerome RN; Edwards TL; Boswell HC; Bernard GR; Harris PA; Pulley JM
Acad Med; 2016 Mar; 91(3):305-9. PubMed ID: 26445080
[TBL] [Abstract][Full Text] [Related]
13. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
14. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
[TBL] [Abstract][Full Text] [Related]
15. An expanded access protocol of RT001 in amyotrophic lateral sclerosis-Initial experience with a lipid peroxidation inhibitor.
Yerton M; Winter A; Kostov A; Lieberman C; Gelevski D; Weber H; Doyle M; Kane G; Parikh N; Burke KM; Rohrer M; Stirrat T; Bruno M; Hochman A; Luppino S; Scalia J; Skoniecki D; D'Agostino D; Sinani E; Yu H; Sherman AV; Babu S; Berry JD; Midei MG; Milner PG; Cudkowicz ME; Paganoni S
Muscle Nerve; 2022 Oct; 66(4):421-425. PubMed ID: 35765222
[TBL] [Abstract][Full Text] [Related]
16. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
[TBL] [Abstract][Full Text] [Related]
17. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
[TBL] [Abstract][Full Text] [Related]
18. Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis.
Quintana M; Saville BR; Vestrucci M; Detry MA; Chibnik L; Shefner J; Berry JD; Chase M; Andrews J; Sherman AV; Yu H; Drake K; Cudkowicz M; Paganoni S; Macklin EA;
Ann Neurol; 2023 Sep; 94(3):547-560. PubMed ID: 37245090
[TBL] [Abstract][Full Text] [Related]
19. Expanded Access Programme: looking for a common definition.
Iudicello A; Alberghini L; Benini G; Mosconi P
Trials; 2016 Jan; 17():21. PubMed ID: 26758369
[TBL] [Abstract][Full Text] [Related]
20. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.
Senefeld JW; Johnson PW; Kunze KL; Bloch EM; van Helmond N; Golafshar MA; Klassen SA; Klompas AM; Sexton MA; Diaz Soto JC; Grossman BJ; Tobian AAR; Goel R; Wiggins CC; Bruno KA; van Buskirk CM; Stubbs JR; Winters JL; Casadevall A; Paneth NS; Shaz BH; Petersen MM; Sachais BS; Buras MR; Wieczorek MA; Russoniello B; Dumont LJ; Baker SE; Vassallo RR; Shepherd JRA; Young PP; Verdun NC; Marks P; Haley NR; Rea RF; Katz L; Herasevich V; Waxman DA; Whelan ER; Bergman A; Clayburn AJ; Grabowski MK; Larson KF; Ripoll JG; Andersen KJ; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Buchholtz ZA; Pletsch MC; Wright K; Greenshields JT; Joyner MJ; Wright RS; Carter RE; Fairweather D
PLoS Med; 2021 Dec; 18(12):e1003872. PubMed ID: 34928960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
